

Regenxbio Inc. (RGNX)

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001590877

Regenxbio Inc. RGNX; healthcare	
Grade	C A B C D E middle fifth of 371 graded peers percentile 55.4; sampling error 2.5 points; lower is stronger
Rank	206 of 371
Profitability	B percentile 29.3
Solvency	D percentile 66.9
Growth and financing	C percentile 53.0
Reliability	0.87 AUC filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$120M to \$591M assets total assets \$453.0M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	short runway not computable: fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Mar 5, 2026 218 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	\$8.08 2026-10-08; market equity \$533.4M
Price used in grade	None



C, the tortoise

middle fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescan

split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: A from Mar 21, 2022, C from Mar 21, 2023, E from Mar 21, 2024, C from Aug 21, 2026

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 5, 2026

We are a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our investigational gene therapies are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy could potentially alter the course of disease significantly and deliver improved patient outcomes with long-lasting effects. Our investigational gene

therapies use adeno-associated virus (AAV) vectors from our proprietary gene delivery platform, which we call our NAV® Technology Platform.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 29.3						
Gross profitability		not computable	32.2%			latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(15.2%)	(6.6%)	29.3	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31
Solvency, sleeve percentile 66.9						
Twelve-month failure probability		0.31%	0.07%	76.5	248	2026-06-30
Altman Z double-prime		(7.82)	(0.31)	58.1	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		2.38x	2.96x	66.1	839	2025-12-31
Growth and financing, sleeve percentile 53.0						
Revenue growth, three-year compound		14.8%	10.0%	39.6	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		(18.4%)	2.1%	81.2	704	2025-12-31
Net share issuance, one year		3.0%	2.5%	38.2	634	2026-02-27


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 1.8 months

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
201	Roivant Sciences Ltd. (ROIV)	54.1	C	fortress balance sheet
202	Emergent BioSolutions Inc. (EBS)	54.3	C	
203	Abbott Laboratories (ABT)	54.6	C	
204	Teladoc Health, Inc. (TDOC)	54.9	C	fortress balance sheet
205	Neuronetics, Inc. (STIM)	55.1	C	
206	Regenxbio Inc. (RGNX) <	55.4	C	short runway
207	ELI Lilly & Co. (LLY)	55.7	C	
208	Caballetta Bio, Inc. (CABA)	55.9	C	dilution
209	AdaptHealth Corp. (AHCO)	56.2	C	
210	Inogen Inc. (INGN)	56.5	C	fortress balance sheet
211	Cooper Companies, Inc. (COO)	56.8	C	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(1.6%)	8.0%	45
Distance from 52-week high	(49.4%)	(31.4%)	28
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(23.7%)	(1.0%)	20
Book value to price	0.13	0.28	33
Sales to price	0.32	0.31	51
Composite equity issuance, five years	44.0%	20.3%	64
Relative strength against the sector, log excess return	(0.23)	(0.14)	45

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail

Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$36.5M
Operating cash flow, four quarters	-\$246.7M
Months of runway	1.8
Days since last periodic filing	64 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	\$10.9M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$83.3M	2024-12-31	2026-03-05	10-K	0001193125-26-094013
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$33.6M	2024-12-31	2025-03-13	10-K	0000950170-25-038770
3	assets	us-gaap:Assets	\$466.0M	2024-12-31	2026-03-05	10-K	0001193125-26-094013
4	net income	us-gaap:NetIncomeLoss	-\$193.9M	2025-12-31	2026-03-05	10-K	0001193125-26-094013
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$124.0M	2025-12-31	2026-03-05	10-K	0001193125-26-094013
6	assets	us-gaap:Assets	\$453.0M	2025-12-31	2026-03-05	10-K	0001193125-26-094013
7	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$90.2M	2023-12-31	2025-03-13	10-K	0000950170-25-038770
8	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$37.2M	2023-12-31	2025-03-13	10-K	0000950170-25-038770
9	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$112.7M	2022-12-31	2025-03-13	10-K	0000950170-25-038770
10	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$54.5M	2022-12-31	2025-03-13	10-K	0000950170-25-038770
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$470.3M	2021-12-31	2024-02-27	10-K	0000950170-24-021161
12	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$51.8M	2021-12-31	2024-02-27	10-K	0000950170-24-021161
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$154.6M	2020-12-31	2023-02-28	10-K	0000950170-23-005085
14	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$35.7M	2020-12-31	2023-02-28	10-K	0000950170-23-005085
15	current assets	us-gaap:AssetsCurrent	\$281.3M	2025-12-31	2026-03-05	10-K	0001193125-26-094013
16	current liabilities	us-gaap:LiabilitiesCurrent	\$118.1M	2025-12-31	2026-03-05	10-K	0001193125-26-094013
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$1.1B	2025-12-31	2026-03-05	10-K	0001193125-26-094013
18	operating income	us-gaap:OperatingIncomeLoss	-\$161.2M	2025-12-31	2026-03-05	10-K	0001193125-26-094013
19	book equity	us-gaap:StockholdersEquity	\$102.7M	2025-12-31	2026-03-05	10-K	0001193125-26-094013
20	liabilities	us-gaap:Liabilities	\$350.3M	2025-12-31	2026-03-05	10-K	0001193125-26-094013
21	operating income	us-gaap:OperatingIncomeLoss	-\$268.1M	2023-12-31	2025-03-13	10-K	0000950170-25-038770
22	interest expense	us-gaap:InterestExpense	\$6.9M	2023-12-31	2024-02-27	10-K	0000950170-24-021161
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$170.4M	2025-12-31	2026-03-05	10-K	0001193125-26-094013
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$2.4M	2025-12-31	2026-03-05	10-K	0001193125-26-094013
25	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$173.1M	2024-12-31	2026-03-05	10-K	0001193125-26-094013
26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$2.4M	2024-12-31	2026-03-05	10-K	0001193125-26-094013
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$218.4M	2023-12-31	2025-03-13	10-K	0000950170-25-038770
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$10.0M	2023-12-31	2025-03-13	10-K	0000950170-25-038770
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$207.5M	2022-12-31	2025-03-13	10-K	0000950170-25-038770
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$30.7M	2022-12-31	2025-03-13	10-K	0000950170-25-038770
31	assets	us-gaap:Assets	\$574.0M	2023-12-31	2025-03-13	10-K	0000950170-25-038770
32	assets	us-gaap:Assets	\$833.3M	2022-12-31	2024-02-27	10-K	0000950170-24-021161
33	shares outstanding	dei:EntityCommonStockSharesOutstanding	51,612,984	2026-02-27	2026-03-05	10-K	0001193125-26-094013
34	shares outstanding	dei:EntityCommonStockSharesOutstanding	50,086,138	2025-03-07	2025-03-13	10-K	0000950170-25-038770